Grey-market retatrutide and lifestyle peptides face mounting quality and regulatory risk

Demand for unapproved retatrutide and other peptides continues through online communities, social-commerce channels, overseas sourcing, and med-spa distribution. Consumer warnings about online purchases reinforce concerns over dose variability, contamination, mislabeling, and weak surveillance, while Lilly litigation, compounding restrictions, enforcement actions, and the Paradigm Peptides sentencing could increase liability and demand for authenticated, traceable supply. Several toxicity, testing, and operational claims remain unindependently substantiated.